Luminal primary muscle-invasive bladder cancer patients are less likely to benefit from platinum-based neoadjuvant chemotherapyJoost L. Boormans, Yair Lotan, Joep J. de Jong et al.|European Urology|2021Cited by 1
Biological characterization of cisplatin-resistant bladder cancer: Implications for second-line treatments?Roland Seiler, P. Black, Hung‐Ming Lam et al.|European Urology Supplements|2018Cited by 0